| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Outline of Final Research Achievements |
ketamine is very familiar with us since it is commonly used in radical surgery as an anesthetic agent. Unfortunately, even basic data on the anti-tumor effects of ketamine is lacking. In the present study, we found that ketamine induced cell death due to apoptosis, which resulted in suppressing the growth of glioma cells. We know that it may be difficult to apply the results of the basic study to human cases. But, in the current clinical practice, ketamine is the only viable anesthetic option among NMDAR antagonists, and it can be used in neurosurgery. Our results suggest that ketamine is an anesthetic candidate providing potential benefit for glioma resection. Our results suggest that ketamine is an anesthetic candidate providing potential benefit for glioma resection.
|
